FDA Issues Alert Regarding Edwards Lifesciences Mitral Valve Delivery System After Patient Death

The US Food and Drug Administration (FDA) and device manufacturer Edwards Lifesciences have issued warnings regarding a potentially high-risk mechanical issue linked to a specific medical device delivery system. The alert focuses on the Commander M delivery system, a core component used to position and implant the SAPIEN M3 mitral valve during transcatheter mitral valve replacement (TMVR) procedures. According to regulatory notices and company communications, the component has been associated with one patient death and one serious injury as of October 5.

Understanding the Mechanism and Identified Risks

During a TMVR procedure utilizing this technology, the SAPIEN M3 valve is mechanically collapsed directly onto the deflated balloon section of the Commander M catheter prior to patient insertion. This configuration allows clinicians to navigate the replacement valve through the patient’s blood vessels and into the heart. However, Edwards Lifesciences reported receiving three distinct customer reports of balloons bursting during inflation.

A balloon rupture during this critical phase can lead to several dangerous complications, including:

• Embolism caused by debris or detached material entering the bloodstream
• Inability to retrieve the delivery device through the guide sheath
• The necessity for emergency secondary interventions, including open surgery

Because the intended recipient population for the SAPIEN M3 system typically consists of individuals deemed too high-risk for standard open surgery, emergency surgical interventions carry an elevated probability of severe adverse health consequences and mortality, as noted in company statements.

Regulatory Response and Previous Recalls

In response to the identified hazard, the FDA has advised that affected product lots be removed from clinical use with immediate effect. Medical professionals and healthcare facilities utilizing the equipment have been notified by the manufacturer to review inventory and halt procedures involving the impacted lots.

The SAPIEN M3 system originally received FDA approval in December 2025. It was authorized as the first transcatheter therapy using a transseptal approach for treating symptomatic moderate-to-severe or severe mitral regurgitation in patients unsuitable for surgery or transcatheter edge-to-edge repair (TEER). The indication also covers specific instances of mitral valve dysfunction, severe mitral stenosis, or moderate mitral regurgitation associated with mitral annular calcification.

This event marks another instance of a balloon-burst concern involving Edwards’ SAPIEN product range. A prior regulatory action occurred in July 2019, when the FDA designated a Class I recall for the SAPIEN 3 ultra delivery system due to a similar balloon-burst issue affecting more than 2,500 units.